



✓ NOW APPROVED!

GETTING STARTED WITH OMVOH™

When you are ready to make an urgent change



Dear Doctor,

CONSIDER OMVOH FOR YOUR ULCERATIVE COLITIS (UC) PATIENTS WHEN YOU'VE DECIDED IT'S TIME FOR A DIFFERENT TREATMENT¹

It is time for an urgent change when your patient¹⁻³:

- ✓ Suffers from moderately to severely active UC³
- ✓ Continues to experience bowel urgency and other symptoms, like rectal bleeding or frequent stools³
- ✓ Experiences bowel urgency as their most bothersome symptom, causing worry that they may not make it to the toilet on time every time^{2,4}
- ✓ Requires a new treatment to manage their disease



OmvoH (mirikizumab) is a first-in-class IL-23p19 antagonist for the treatment of moderately to severely active UC⁵

GETTING STARTED WITH OMVOH

INDUCTION IV FROM INDUCTION IV




OMVOH DOSING BEGINS WITH 3 INTRAVENOUS (IV) INDUCTION DOSES VIA INFUSION EVERY 4 WEEKS AND TRANSITIONS TO SUBCUTANEOUS (SC) SELF-INJECTIONS FOR MAINTENANCE¹

Start with infusions¹

- Every 4 weeks
- 3 doses: Weeks 0, 4, 8
- 300 mg IV per dose
- IV for at least 30 minutes

TO MAINTENANCE SC



2 prefilled pens (100 mg each)

FOR PATIENTS WHO HAVE ACHIEVED CLINICAL RESPONSE DURING INDUCTION¹

1 maintenance dose is 2 injections

Full dose = 200 mg¹

Transition to self-injections

- Start at week 12
- Every 4 weeks thereafter

Injection administration sites

- Abdomen
- Back of upper arm
- Thigh

Missed dose


- If a dose is missed, administer the dose as soon as possible; thereafter, resume monthly injections¹

Storage

- 2–8°C (36 °F to 46 °F)*
- Do not freeze. Do not use OmvoH if it has been frozen
- Protect from light (in original carton)
- Keep away from direct heat or light
- Do not shake

*If needed, the pen may be stored outside of refrigeration at not more than 30°C (86°F) for up to 2 weeks in original carton to protect it from light. Once OmvoH has been stored at room temperature, do not return to the refrigerator. If these conditions are exceeded OmvoH must be discarded. The prefilled syringe and prefilled pen are not made with dry natural rubber latex.¹

WHAT TO EXPECT WITH OMVOH SC INJECTION¹



Some patients might experience injection site reactions or injection site pain. These are typically mild to moderate.¹

TIPS TO MINIMIZE INJECTION SITE PAIN OR REACTION¹

These are general suggestions for your patients




Place **cold ice pack, gel pack, or water bottle** on injection site



Let OmvoH **warm to room temperature** before injecting



Use **anti-pain medication** such as acetaminophen



Use **local numbing medication** such as lidocaine/prilocaine on the injection site



Use **corticosteroid topical cream** or ointment such as hydrocortisone on the injection site



Choose a **different injection site** as well as a **different area within that site** for each injection



Use **anti-inflammatory medication** (such as methylprednisolone or prednisolone) or **anti-itch medication** (such as cetirizine, diphenhydramine, hydroxyzine, levocetirizine, or loratadine)

SAFETY PROFILE FROM TWO PHASE 3 TRIALS^{5,6}



OmvoH was well-tolerated, with similar adverse events to placebo through 1 year. Rates of serious infections and malignancies were low and comparable to placebo.⁵

The most frequently reported adverse reactions were injection site reactions in the maintenance study, upper respiratory tract infections (most frequently nasopharyngitis), headache and rash.¹

IL-23p19, interleukin 23, subunit p19; **IV**, intravenous; **Q4W**, every 4 weeks; **SC**, subcutaneous; **UC**, ulcerative colitis.

REFERENCES

1. OmvoH™ USPI October 2023.
2. Dubinsky MC, Irving PM, Panaccione R, et al. Incorporating patient experience into drug development for ulcerative colitis: Development of the urgency numeric rating scale, a patient-reported outcome measure to assess bowel urgency in adults. *J Patient Rep Outcomes*. 2022;6(1):31.
3. Allocca M, Furtaro F, Fiorino G, et al. Can IL-23 be a good target for ulcerative colitis? *Best Pract Res Clin Gastroenterol*. 2018;32:33-95-102.
4. Dibley L, Norton C. Experiences of fecal incontinence in people with inflammatory bowel disease: Self-reported experiences among a community sample. *Inflamm Bowel Dis*. 2013;19(7):1450-1462.
5. D'Haens G, Dubinsky M, Kobayashi T, et al. Mirikizumab as induction and maintenance therapy for ulcerative colitis: Results from the phase 3 LUCENT program. 2022.
6. Morris N, Li Z, Zhao M, et al. Phase 3, multicenter, randomized, double-blind, parallel, placebo-controlled induction study of mirikizumab in conventional-failed and biologic-failed patients with moderately to severely active ulcerative colitis (LUCENT-1). 2021.

PP-MR-AE-0072

This email message (including all attachments) is for the sole use of the intended recipient(s) and may contain confidential information. Any unauthorised review, use, disclosure, copying or distribution is strictly prohibited. If you are not the intended recipient, please approach Lilly contact via email and destroy all copies of the original message.

Lilly and Omvoh® are registered trademarks of Eli Lilly and Company.

© 2024 Eli Lilly and Company. All Rights Reserved.

SCAN HERE



Privacy Policy



Prescribing Information

For adverse events and safety reporting, please send an email: PV-MEA@lilly.com

For product complaints, please send an email: lbmail_pc_mena@lilly.com

For further information about Lilly and Lilly products please contact us at the below address:

UAE: Bldg. 25 - 6th Floor, Dubai Health CareCity, Dubai, UAE, P.O. Box #25319, Tel.: (+971 4)453 7800, Fax: (+971 4) 436 2399

Lilly